Net Profit Margins
Beam Therapeutics Inc’s revenue jumped 1970.64% since last year same period to $15.8Mn in the Q3 2022. On a quarterly growth basis, Beam Therapeutics Inc has generated -5.12% fall in its revenue since last 3-months.
Beam Therapeutics Inc’s net profit fell -289.7% since last year same period to $-109.58Mn in the Q3 2022. On a quarterly growth basis, Beam Therapeutics Inc has generated -52.29% fall in its net profits since last 3-months.
Beam Therapeutics Inc’s net profit margin jumped 81.18% since last year same period to -693.56% in the Q3 2022. On a quarterly growth basis, Beam Therapeutics Inc has generated -60.52% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
Beam Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.32 - a -3.13% fall from last quarter’s estimates.
Beam Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.32.
Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)
Beam Therapeutics Inc’s earning per share (EPS) jumped 17.07% since last year same period to -1.02 in the Q2 2022. This indicates that the Beam Therapeutics Inc has generated 17.07% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Beam Therapeutics Inc’s return on assets (ROA) stands at -0.08.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Beam Therapeutics Inc’s return on equity (ROE) stands at -0.4.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|
Beam Therapeutics Inc
238 Main Street, Cambridge, MA, United States, 02142
John M. Evans
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*